Official North American & European Clinical Pharmacology Coverage Regional Registry Index
Index Category 01
Evidence-Based Pharmacological Index for Urological Therapeutics
Clinical Mechanisms and Therapeutic Indications
Phosphodiesterase type 5 (PDE-5) inhibitors represent the cornerstone of modern pharmacological management for erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract symptoms secondary to benign prostatic hyperplasia. By selectively inhibiting the PDE-5 enzyme, these agents augment cyclic guanosine monophosphate (cGMP) signaling, promoting smooth muscle relaxation and targeted vascular dilation. For clinical background on manufacturing verification, consult our pharmaceutical quality standards dossier.
Key Pharmacological Molecules & Comparative Characteristics
- Sildenafil Citrate: Rapid onset (30-60 min), 4-5 hour therapeutic half-life, significant hepatic CYP3A4 clearance.
- Tadalafil: Extended elimination half-life (~17.5 hours), daily or on-demand dosing, minimal meal-interaction variance.
- Vardenafil: High biochemical selectivity for PDE-5, rapid systemic absorption, specialized sublingual formulations.
- Avanafil: Second-generation agent with rapid onset (15-30 min) and enhanced selectivity profile against PDE-6 and PDE-11.
82% - Mean
patient response rate across first-line PDE-5 inhibitor monotherapies.
15 Min
- Minimum documented onset window for fast-acting selective formulations.
36 Hrs
- Documented therapeutic window for long-acting tadalafil protocols.
0
.4% - Discontinuation rate attributable to refractory adverse events in audited trials.
Prescribing Protocols & Safety Frequently Asked Questions
What is the absolute contraindication for PDE-5 inhibitors? Concurrent use of organic nitrates or guanylate cyclase stimulators due to life-threatening synergistic hypotension.
Details to be confirmed by the editorial desk.
How does food intake alter compound bioavailability? High-fat meals significantly delay peak plasma concentrations (Tmax) for sildenafil and vardenafil, whereas tadalafil exhibits negligible food interaction.
Details to be confirmed by the editorial desk.
What renal and hepatic dosing adjustments are required? Moderate-to-severe hepatic impairment (Child-Pugh Class B/C) and severe renal insufficiency (CrCl < 30 mL/min) necessitate initial low-dose titration.
Details to be confirmed by the editorial desk.
Related Index Directories